Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients
Darmstadt, Germany (ots/PRNewswire) - - The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation - Study aims to recruit 946 patients across 17 European countries Merck, the global pharmaceutical and chemical company, today announced the enrollment of the first ...